DexCom, Inc.
NASDAQ:DXCMMedical - Devices
+$0.90 today
- Market cap
- $30.78B
- Beta
- 1.44
- P/E (TTM)
- 29.9
- EPS (TTM)
- $2.42
Volume 4.25M
Average 5.43M
DXCM EBITDA Margin
EBITDA as a percentage of revenue.
DexCom, Inc.NASDAQ: DXCM
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin widens to 29.7%
EBITDA Margin was 29.7% in Q2 FY2026, up 3.0 pp from a year earlier. On a trailing-twelve-month basis it was 31.4%, up 7.2 pp year over year. Over 3 fiscal years it widened by 9.7 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 21 analysts of 30.5% for the fiscal year ending Dec 2026, up from 29.1% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 29.7%+1.2 pp QoQ
- Last fiscal yearDec 2025
- 29.1%+5.7 pp YoY
- LTMJun 2026
- 31.4%+7.2 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +3.0 pp | -5.0 pp | -8.0 pp |
| 1 year | +5.7 pp | +1.3 pp | -4.4 pp |
| 3 years | +9.7 pp | +4.1 pp | -5.6 pp |
| 5 years | +9.8 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 29.1%
- Year-over-year change
- +5.7pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29.1% | +5.7pp |
| FY2024 | 2024-12-31 | 23.4% | -1.9pp |
| FY2023 | 2023-12-31 | 25.3% | +5.9pp |
| FY2022 | 2022-12-31 | 19.4% | +4.0pp |
| FY2021 | 2021-12-31 | 15.4% | — |
EBITDA Margin vs competitors
How DXCM compares with its peers on the latest reported figures
- DXCM's LTM Jun 2026 EBITDA Margin of 31.4% is the highest of the 7 companies compared; the peer median is -32.3%.
- Its year-over-year change of +7.2 pp is the 3rd highest of 6, against a peer median of +6.7 pp.
- Over three fiscal years its change of +9.7 pp compares with a peer median of +7.7 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 31.4% | +7.2 pp | +9.7 pp | |
| LTM Jun 2026 | 21.5% | +4.3 pp | +10.5 pp | |
MMEDMiniMed Group, Inc. Common Stock | LTM Jul 2026 | 5.2% | — | +4.9 pp |
| LTM Mar 2026 | -7.0% | +6.7 pp | -8.0 pp | |
| LTM Mar 2026 | -57.6% | +41.1 pp | +35348.3 pp | |
| LTM Mar 2026 | -151.9% | -4.9 pp | +45.9 pp | |
| LTM Mar 2026 | -198.5% | +73.8 pp | -1165.0 pp | |
MMEDVMiniMed Group, Inc. | — | — | — | — |
| Peer median (excluding DXCM) | -32.3% | +6.7 pp | +7.7 pp | |
Competitors are the stored peer set for DXCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.45B | 2.91B | 3.62B | 4.03B | 4.66B |
| Cost of Revenue | 768M | 1.03B | 1.33B | 1.59B | 1.86B |
| Gross Profit | 1.68B | 1.88B | 2.29B | 2.44B | 2.8B |
| Gross Margin | 68.6% | 64.7% | 63.2% | 60.5% | 60.1% |
| Research & Development | 604.2M | 484.2M | 505.8M | 552.4M | 599.1M |
| Selling, General & Admin | 810.5M | 1.01B | 1.19B | 1.29B | 1.29B |
| Operating Expenses | 1.41B | 1.49B | 1.69B | 1.84B | 1.89B |
| Depreciation & Amortization | 102M | 155.9M | 186M | 217.7M | 251.8M |
| EBITDA | 377.6M | 565.3M | 916.7M | 945.7M | 1.36B |
| EBITDA Margin | 15.4% | 19.4% | 25.3% | 23.4% | 29.1% |
| Operating Income | 265.8M | 391.2M | 597.7M | 600M | 911.8M |
| Operating Margin | 10.9% | 13.4% | 16.5% | 14.9% | 19.6% |
| Interest Income | 1.7M | 23.8M | 135M | 134.2M | 112.7M |
| Interest Expense | 18.8M | 18.6M | 20.3M | 19M | 18.3M |
| Other Income / Expenses | (9M) | (400K) | 112.7M | 109M | 176.6M |
| Income Before Tax | 256.8M | 390.8M | 710.4M | 709M | 1.09B |
| Pre-Tax Margin | 10.5% | 13.4% | 19.6% | 17.6% | 23.3% |
| Income Tax Expense | 39.9M | 49.6M | 168.9M | 132.8M | 252.1M |
| Net Income | 216.9M | 341.2M | 541.5M | 576.2M | 836.3M |
| Net Margin | 8.9% | 11.7% | 14.9% | 14.3% | 17.9% |
| EPS (Basic) | 0.56 | 0.88 | 1.44 | 1.46 | 2.14 |
| EPS (Diluted) | 0.51 | 0.80 | 1.30 | 1.42 | 2.09 |
| Weighted Avg Shares | 386.9M | 389.4M | 386M | 404.63M | 390.2M |
| Weighted Avg Shares (Diluted) | 428.8M | 427.5M | 425.5M | 412.7M | 405.5M |
DexCom, Inc.
NASDAQ:DXCM
Intrinsic Alpha fair value
Locked
Current Price
$82.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.